Manuscript title: Lifecourse Genome-Wide Association Study Meta-Analysis Refines the Critical Life Stages for the Influence of Adiposity on Breast Cancer

Short title: Lifecourse Influence of Adiposity on Breast Cancer

Author list: Grace M. Power[1,2,3], Laxmi Bhatta[4,5,6], Amanda Hughes[1,2,7], Carolina Medina-Gomez[8], Anne Richmond[9], Genevieve Leyden[1,2], Bethan Lloyd-Lewis[1,10], Eleanor Sanderson[1,2], Rebecca Richmond[1,2], Elizabeth C. Corfield[1,2,7,11], Daniel McCartney[9], Caroline Hayward[9,12], Irene Fontes Marques[13,14], Fernando Rivadeneira[8], Bjørn Olav Åsvold[4,15,16], Gibran Hemani[1,2], Janine F. Felix[13,14], Ben Brumpton[4,15,17], Alexandra Havdahl[7,11,18], George Davey Smith[1,2,19]

Affiliations
1. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
2. Population Health Sciences, Bristol Medical School, University of Bristol, UK.
3. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
4. HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
5. Division of Mental Health Care, St Olavs Hospital, Trondheim, Norway.
6. Department of Clinical and Molecular Medicine, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
7. PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo Norway.
8. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, CA 3000, The Netherlands.
9. Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
10. School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
11. Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway
12. MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
13. Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
14. Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
15. HUNT Research Centre, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway.
16. Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
17. Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
18. PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway
19. NIHR Bristol Biomedical Research Centre Bristol, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

Abstract

Previous evidence suggests that higher prepubertal adiposity may protect against breast cancer risk; however, this protective effect does not appear to persist into later life. The specific age at which this effect diminishes remains unclear and has yet to be explored using causal inference methods.

This study examined the effect of body mass index (BMI) in nulliparous women during the early reproductive years on breast cancer risk. Using data from five large cohorts, we conducted genome-wide association studies (GWAS) on BMI from menarche to <40 years (N = 90,115), including three age sub-intervals: menarche to <20 years, 20 to <30 years, and 30 to <40 years. Results were meta-analysed, and consistency in genetic effects across age intervals was assessed. Two-sample Mendelian randomization (MR) within a lifecourse framework was applied to estimate the causal effect of genetically proxied BMI on overall breast cancer risk and seven subtypes using data from the Breast Cancer Association Consortium (N□=□up to 247,173).

Substantial heterogeneity in genetic effects on BMI across early adulthood was observed, with 9 of the 45 discovery variants showing significant variation (Q_{het} < 0.05). Genome-wide genetic correlations suggested that BMI in early adulthood may be influenced by partially distinct genetic factors compared to other life stages (r_G = 0.76 with prepubertal body size; r_G = 0.85 with later-life body size). Univariable MR analyses provided strong evidence that higher genetically predicted BMI between menarche and 40 years (mean age 23.9 years) reduced overall breast cancer risk (IVW odds ratio per standard deviation increase: 0.24, 95% CI: 0.12 to 0.45, P□=□9.60×10□□), as well as most subtypes except HER2-enriched breast cancer. The protective effect was strongest between menarche and <20 years, decreasing in later intervals. These effects persisted after adjusting for later-life body size but attenuated when prepubertal body size was included in multivariable MR models, suggesting that prepuberal body size primarily drives the observed protection.

Our findings suggest that while higher BMI in early adulthood is associated with reduced breast cancer risk, this effect may be largely attributable to adiposity accrued before puberty. These results refine our understanding of the timing of adiposity's protective influence on breast cancer and highlight prepuberty as a critical window for risk modulation.

Teaser

Improving knowledge of adiposity's genetic architecture across the lifecourse refines insights into its role in breast cancer

Introduction

Breast cancer is the most commonly diagnosed cancer worldwide, with over 2.3 million new cases and 685,000 deaths reported in 2020 (1). Nearly 99% of women diagnosed at the earliest stage survive for 5 years or more, compared to approximately 32% of those diagnosed at the most advanced stage (2). This underscores the importance of improving early detection and highlights the need to identify preventative strategies as key public health objectives.

Breast tissue is particularly vulnerable to exposures between menarche and first full-term pregnancy – a critical window of susceptibility (3). After menarche, the breast epithelium undergoes rapid cellular proliferation leading to an increased risk of acquiring mutation during puberty and until the terminal ductal differentiation that accompanies the first full-term pregnancy (4, 5). Evidence suggests that certain exposures such as physical activity (3), may alleviate the risk of breast cancer, while others, such as alcohol consumption (6), a known breast carcinogen (7), may exacerbate it, by acting during this period of tumorigenic susceptibility. By investigating whether known factors influencing breast cancer risk also exert effects during this timeframe, we may be better able to identify strategies for more effective breast cancer risk detection and potential avenues for prevention. Focusing on this period may additionally enable a more precise assessment by minimising the confounding effects of physiological changes associated with first birth.

Mendelian randomization (MR) is a technique that exploits the quasi-random distribution of genetic variants from parents to offspring, independent of the influence from other traits. Under specific assumptions, MR aims to estimate causal effects by reducing susceptibility to confounding factors, including confounding by undiagnosed existing disease and disease processes (reverse causation) (8, 9). Recent developments in lifecourse MR methodology include multivariable MR (MVMR) (10-12). This approach enables the direct estimation of the effects of an exposure measured at a specific life stage, controlling for the same exposure measured at another life stage, on later life outcomes. Previous MVMR analyses suggest that a larger prepubertal body size, employed as a proxy for BMI, is protective against breast cancer (13-15). This protective effect persists even after controlling for later life adult body size, which has a negligible effect on breast cancer risk when prepubertal body size is controlled for. These findings align with conventional analyses (16-18) and have been further supported through a proxy-genotype MR approach (19).

Although a larger body size in childhood has been shown to reduce breast cancer risk, it also leads to earlier menarche, a known risk factor for breast cancer (13). This dual effect suggests that the protective direct effect of prepubertal body size on breast cancer could be larger than its total observed effect, as it may be partially attenuated by an increased risk mediated through earlier menarche. This interplay

133 highlights two potentially independent pathways that may interact in complex ways.
134 Despite convincing evidence for the protective effects of prepubertal body size on
135 breast cancer risk, the time period at which this protective effect diminishes is yet to
136 be determined using causal inference methods.
137
We aimed to estimate the effect of higher BMI between menarche and first full-term
pregnancy—or throughout early adulthood (<40 years) in individuals who remain
nulliparous—on breast cancer risk later in life. This previously understudied period
represents a critical window of susceptibility to exposures influencing breast cancer
risk. We assess these effects on overall breast cancer and seven subtypes, including
ER status (ER+/ER-) and five molecular subtypes: Luminal A, Luminal B1 (HER2+),
Luminal B2 (HER2-), HER2-enriched, and triple-negative breast cancer using data
from the Breast Cancer Association Consortium (BCAC) (20, 21), with the aim of
exploring whether the effects of a higher BMI during this period differ in relation to
menopausal status through associations with these breast cancer subtypes.

Materials and methods.

This study adheres to the Strengthening The Reporting of Observational Studies in Epidemiology Using Mendelian Randomisation (STROBE-MR) guidelines (Table S1).

<u>Data sources and study design</u>

Inclusion criteria and participating cohorts

We analysed five large population-based prospective cohorts with genomic and phenotypic BMI data from nulliparous women between menarche and <40 years. These included the Avon Longitudinal Study of Parents and Children (ALSPAC), the Trøndelag Health Study (HUNT), the Norwegian Mother, Father and Child Cohort Study (MoBa), Generation R, and Generation Scotland. Participant selection is shown in Figure 1.

Cumulative BMI data available for nulliparous women in each age category [a]

	Menarche to <20 years						20 to <30 years						30 to <40 years			
ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland		ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland		ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
2,047	1,093	7,826	N/A	430		3,520	5,507	29,375	1,127	1,745		1,054	1,083	37,669	1,269	884

Genotyped BMI data taken from several age groups for nulliparous women between menarche and <40 years [a]

ALSPAC	HUNT	n MoBa	Generation R	Generation Scotland
5,047	7,683	74,906	2,479	3,059

a. In cohorts with repeat measures, the same value is provided for each age-group category, i.e. for cohorts with repeat measures, the second measure within the age group with the largest sample is used (e.g., for ALSPAC, the only measure of genotyped BMI data is from menarche to <20 years old).

Figure 1. Overview of study participants used for this analysis

ALSPAC. ALSPAC is a birth cohort which enrolled 14,541 pregnant women living in
Avon, England with expected dates of delivery between April 1, 1991, and December
31, 1992 (the estimated recruitment rate of those eligible was 80%) (22-24). Further
enrolments after 1998 resulted in a baseline sample of 14,901 children alive at one
year of age. Some study data were collected and managed using Research
Electronic Data Capture (REDCap) electronic data capture tools hosted at the
University of Bristol (25). Please note that the study website contains details of all
the data that is available through a fully searchable data dictionary and variable
search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/. We used data
collected on women prior to pregnancy and their daughters in the 17 and 24-year
follow up groups that had information on genotype, menarche, BMI and age. We
included 3,125 ALSPAC mothers and 3,496 daughters from the offspring generation
in the age-stratified analysis. In the analysis focused on individuals between
menarche and first birth (if pregnancy occurred within this timeframe), we included
3,125 ALSPAC mothers and 1,922 daughters.

HUNT. HUNT is a cohort study of the adult population in Trøndelag County, Norway,
and comprises ~230,000 individuals aged ≥20 years (26, 27). Individuals were
recruited in four surveys from 1984–2019, of which the HUNT2 and HUNT3 surveys
were included in the present study. Invitee participation rates were 69% and 54%,
respectively. Data on perinatal outcomes are available via linkage to the Medical
Birth Registry of Norway (MBRN) (28) for individuals born after 1967. The full
recruited sample of mothers was 64,098. A total of 69,716 offspring were available in
HUNT, with genotype and measured phenotype information, of which 36,938 were
female (29, 30). A total of 7,683 individuals were used in this study.

MoBa. MoBa is a population-based pregnancy cohort study conducted by the
Norwegian Institute of Public Health (31). Participants were recruited from all over
Norway from 1999 to 2008, with 41% of all pregnant women invited consenting to
participate. Blood samples were obtained from both parents during pregnancy and
from mothers and children (umbilical cord) at birth (32). The first child was born in
October 1999 and the last in July 2009. The cohort includes approximately 114,500
children, 95,200 mothers, and 75,200 fathers. Additionally, MoBa was linked to data
from the Medical Birth Registry (MBRN), a national health registry containing
information about all births in Norway from 1967 onwards (28). This analysis used a
total of 67,690 MoBa mothers and 7,216 daughters from the offspring generation
with information on genotype, menarche, BMI, and age.

Generation R. The Generation R Study is a population-based prospective cohort
from fetal life onwards in Rotterdam, the Netherlands (33). Women with an expected
delivery date between April 2002 and January 2006 living in Rotterdam were eligible
to enrol the study, and written informed consent was obtained from all participants. A
total 9,778 mothers, who gave birth to 9,749 live-born children, enrolled in the study.
Genotype data were available for a total of 7,236 mothers, of which 3,450 were first-

time mothers of singleton children and had information on pre-pregnancy BMI (34).
Maternal age and pre-pregnancy weight were reported by the mother and height was
measured at intake. A total of 2,479 women contributed to this GWAS.
214
Generation Scotland. Generation Scotland is a population-based cohort with
~20,000 participants from across Scotland, aged between 18 and 98 years. During
2006 to 2010, potential participants (aged 35–65 years) were identified and invited to
join at random from collaborating general medical practices in Scotland. Participants
were asked to identify ≥1 first-degree relatives aged ≥18 years who would also be
able to participate. Subsequently, participants attended a staffed research clinic,
completed a health questionnaire, and had physical and clinical characteristics
measured according to a standardized protocol. Fasting blood and urine samples
were collected, according to standard operating procedures. The full recruited
sample of female participants was 14,152, of which 3,059 were included in this
study.
226
227 *Genotyping, quality control and imputation in each cohort*
228
Genotyping, quality control and imputation for each cohort are described in detail in
Supplementary Text and elsewhere (30, 34-36). Briefly, participants were genotyped
using genome-wide SNP arrays, and imputation was performed using standard
reference panels following cohort-specific quality control (QC) protocols. ALSPAC
mothers and children were genotyped using Illumina Human660K and
HumanHap550 arrays, respectively, with imputation via Haplotype Reference
Consortium (HRC) v1.1. HUNT samples were genotyped using three Illumina
HumanCoreExome arrays, with imputation performed using Minimac3 and a
customized HRC v1.1 reference panel (30, 35). MoBa sampels were genotyped
across 24 batches with varying selection criteria, centers, and arrays. The European
Genome-Phenome Archive HRC v1.1 (Study ID EGAS00001001710) was used for
phasing and imputation (31, 36). Generation R mothers were genotyped using
Illumina GSA-MD 2.0 and 3.0 arrays, with imputation against the 1000 Genomes
Phase 3 v5 reference panel (33, 34). Generation Scotland samples were genotyped
using the Illumina HumanOmniExpressExome-8v1 chip, with imputation via HRC.r1-
1 on the Sanger Imputation Server.
245
246 *Statistical methods*
247
248 *Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis*
249
250 We aimed to establish lifestage-specific genetic effect profiles for BMI. This was to (i)
251 assess the consistency of genetic variant effects on BMI across different age groups
252 (including prepubertal and later-life adulthood, where body size was used as a proxy
253 for BMI based on previously derived genome-wide association studies (GWAS) from
254 UK Biobank data (14)) and (ii) applying these profiles in downstream lifecourse MR

analyses. To achieve this, we conducted GWAS on lifestage-stratified BMI values across an age range that has not been previously investigated. Specifically, separate GWAS analyses were run on nulliparous women between menarche and <40 years. These analyses were further stratified into three age groups: <20 years, 20 to <30 years, and 30 to <40 years. For BMI measurements from mothers in birth cohorts, we extracted pre-pregnancy data from women who had not given birth previously. A complete-case approach was used, excluding individuals with missing values from the analysis. Due to the skewed distribution of BMI in the data, a natural log transformation was applied prior to running the GWAS analyses within each cohort. GWAS analyses were carried out independently by individual studies, each following their own quality control (QC) procedures (Supplementary Text and elsewhere (30, 34-36). All analyses were restricted post hoc to common genetic variants with a minor allele frequency (MAF) $\geq$ 0.01. Although mothers and daughters are related in several of the cohorts used, they were treated as independent samples in this study, with adjustments made to account for their relatedness..

We meta-analysed summary statistics from the five cohorts for each lifestage-specific GWAS separately, using a fixed effects model employed in METAL version 2020-05-05 (37). We carried out further standard quality control QC procedures (38) including tests for bias due to population structure (genomic control inflation factor [λ] and Linkage Disequilibrium Score Regression [LDSC] (39)). We also estimated SNP heritability and assessed genetic correlations between our meta-analysed GWAS and GWAS derived using UK Biobank data of prepubertal body size and adult body size (14). Analyses were performed using the LDSC software v1.0.0 (https://github.com/bulik/ldsc) employing default parameters. We used linkage disequilibrium (LD) scores from European participants of the 1000 genomes project that can be downloaded from the LDSC website. We generated Manhattan plots which contain horizontal lines drawn at $-\log10(1 \times 10^{-5})$ for "suggestive associations" and $-\log10(5 \times 10^{-8})$ for the 'genome-wide significant' threshold and QQ plots (Figure S1-S4) (40).

We used LD clumping with an r^2 threshold of 0.001 to select a set of independent instruments for BMI at each age group. This was performed using PLINK (41) and genotype data from European individuals from phase 3 v5 enrolled in the 1000 genomes project as a reference panel (42).

We visualised the age-specific effect trajectories of these SNPs at each age group (menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size inversely proportional to the standard error of the effect estimate. We focused exclusively on SNPs derived from the age groups analysed in this study and did not include those from other studies due to differences in effect size scales. For example, body size measures for prepubertal and later adulthood stages, derived

298 from UK Biobank data, were based on body size categories rather than BMI, making
299 direct comparisons inconsistent (14).
300
301 *Publicly available genome-wide association study (GWAS) data*
302
We used publicly available breast cancer data from the Breast Cancer Association
Consortium (BCAC) from 2017 (N = 228,951; ER+/ER- samples, extracted from
OpenGWAS under IDs: ieu-a-1127, ieu-a-1128) (20) and the latest release of BCAC
from 2020 (N = 247,173; overall sample and five molecular subtypes: Luminal A,
Luminal B1 (HER2+), Luminal B2 (HER2-), HER2-enriched, and triple-negative
breast cancer (21) (details in Table S2). In the BCAC classification, Luminal B1
(HER2+) tumours are characterized by ER+, progesterone receptor positive (PR+),
and HER2+ status, whereas HER2-enriched tumours are defined as HER2+, ER-,
PR+ tumours. The cohort design and genotyping protocol details are described
elsewhere   (bcac.ccge.medschl.cam.ac.uk/bcac-groups/study-groups/,
bcac.ccge.medschl.cam.ac.uk/bcacdata/). The study groups in the BCAC consortium
do not include ALSPAC, HUNT, MoBa, Generation R, Generation Scotland or UK
Biobank cohorts.
316
For comparative purposes, we utilised previously conducted GWASs of prepubertal
and later life adult body size, used as a proxy for BMI, previously undertaken in the
UK Biobank study on 246,511 females. These GWAS represent the largest available
sample size for body size in these age groups. GWASs were adjusted for age and
genotyping chip and genetic variants were selected based on $P < 5 \times 10^{-8}$ and
$r^2 < 0.001$ (14, 43, 44). UK Biobank data were collected between 2006 and 2010
on individuals aged between 40 and 69 years old at baseline, including data from
clinical examinations, assays of biological samples, detailed information on self-
reported health characteristics, and genome-wide genotyping, using a prospective
cohort study design (44). The prepubertal body size measure utilised recall
questionnaire data, involving responses from adult participants who were asked
whether, compared to the average, they were 'thinner', 'about average' or 'plumper',
when they were aged 10 years old. The adult body size variable was derived using
clinically measured body mass index (BMI) data (mean age 56.5 years). It was then
separated into a 3-tier variable using the same categories as the childhood body size
measure for comparability; "thinner" (21.1 kg/m^2-25 kg/m^2), "about average"
(25 kg/m^2-31.7 kg/m^2) and "plumper" (31.7 kg/m^2-59.9 kg/m^2) (14). These scores
have been independently validated in three distinct cohorts, providing verification
that these genetic instruments can reliably separate childhood and adult BMI (14, 45,
46).
337
To disentangle whether our results were influenced by age at menarche, we used
publicly available data (Age when periods started (menarche)) from the UK Biobank
cohort where female individuals were asked 'How old were you when your periods
started?'. This GWAS was conducted in 2014 (N=182,416, extracted from

OpenGWAS under ID: ieu-a-1095)). To investigate the potential for collider bias
resulting from restricting our analyses to nulliparous women we used publicly
available parity data (Number of live births) from the UK Biobank cohort from 2018
(N = 250,782, extracted from OpenGWAS under ID: ukb-b-1209).
346
347 *Lifecourse Mendelian randomization (MR) analysis*
348
Our primary two-sample MR analyses used the inverse variance weighted (IVW)
estimator, implemented in the TwoSampleMR R package (47). When genetic
variants are used as instrumental variables in MR, the assumptions of instrumental
variables must be met, i.e., the genetic variants used must (i) be strongly associated
with the exposure of interest and relevant to the population studied, here pregnant
women ("relevance"), (ii) not share common causes with the outcome
("independence"), and (iii) not affect the outcome other than through the exposure
("exclusion-restriction") (48). We conducted sensitivity analyses, which relax the
assumptions made about horizontal pleiotropy, including MR Egger regression (49),
and the weighted median-based estimator (50). We ran IVW multivariable MR
(MVMR), an extension of MR that employs multiple genetic variants associated with
multiple measured risk factors, to calculate the direct and indirect effects of BMI
between menarche and first birth on breast cancer outcomes. This analysis
accounted for prepubertal and later-life adult body size separately (Figures 2A, B
and C). These two additional time points were not included together in a single
model due to the risk of weak instrument bias. Instrument strength was evaluated
using the two-sample conditional F statistic described elsewhere (51).

Figure 2. Directed acyclic graphs indicating three scenarios to explain the causal effect between BMI in nulliparous women between menarche and <40 years and breast cancer in later life. A. BMI in nulliparous women between menarche and <40 years has a total causal effect on breast cancer. B. BMI in nulliparous women between menarche and <40 years has a total causal effect on breast cancer, independent of prepubertal body size. C. BMI in nulliparous women between menarche and <40 years has a total causal effect on breast cancer, independent of adult body size.

Sensitivity analyses

To minimise pregnancy-related confounding, we restricted the BMI exposure GWAS
to nulliparous women, enabling a clearer assessment of BMI's direct influence
across life stages. In contrast, the breast cancer outcome GWAS included both
nulliparous and parous women. This discrepancy in selection mechanisms
introduces potential selection bias in the genetic effect estimates for BMI but not for
breast cancer. Specifically, conditioning on parity in the BMI GWAS may induce bias
in the estimated SNP effects on BMI ($\hat{\beta}_{Gx}$), whereas breast cancer estimates ($\hat{\beta}_{Gy}$),
remain unaffected as parity was not conditioned on in the outcome GWAS (Equation
1).

In this two-sample MR setting, the MR estimate is given by:
391   (Equation 1)

$$\hat{\beta}_{MR} = \frac{\hat{\beta}_{Gy}}{\hat{\beta}_{Gx}}$$

Where:

$$E(\hat{\beta}_{Gx}) = \beta_{Gx} + \text{bias}$$

$$E(\hat{\beta}_{Gy}) = \beta_{Gy}$$

Since $\hat{\beta}_{Gy}$ is not subject to the same selection mechanism and there is no reason to
assume that the selection-induced bias in β_{Gx} is correlated with $\hat{\beta}_{Gy}$, a major spurious
association in the MR analysis is unlikely. However, selection bias in the BMI GWAS
could distort the MR estimate, with the direction and magnitude depending on
whether and how BMI influences parity within the restricted sample. In an extreme
scenario it could induce false positive associations with BMI that arise due to collider
bias though this is unlikely at current sample sizes.

To empirically assess this, we performed univariable MR analyses estimating the
effect of parity on BMI in nulliparous women across different life stages (menarche to
<40 years, <20 years, 20 to <30 years, and 30 to <40 years). While parity itself
cannot causally influence BMI in nulliparous women, genetic variants associated with
parity may exhibit pleiotropic effects on BMI through shared metabolic and
reproductive pathways. If these parity-associated variants also influence BMI within
our restricted sample, it would suggest selection bias related to reproductive
behaviour, implying that conditioning on parity in the BMI GWAS may have
introduced collider bias.

In addition, a later onset of menarche has been linked to a reduced risk of breast
cancer (52, 53). Childhood body size has been shown to accelerate the timing of
menarche, whilst an earlier menarche increases the likelihood of increased body size

in adulthood (54, 55). With these traits sharing a complex and interconnected
relationship, we conduct sensitivity analyses estimating the effect of BMI in the
lifestages analysed in nulliparous women on overall breast cancer accounting for
age at menarche in MVMR analyses. Age at menarche is treated as a confounder,
as it may influence both BMI and breast cancer risk through hormonal and metabolic
pathways. Including it in the MVMR model ensures that observed BMI effects are not
simply a reflection of differences in pubertal timing.
426
We conducted statistical analyses in R version 4.3.3 (56).

Results

The analyses comprised up to 90,115 individuals across five cohorts (ALSPAC,
HUNT, MoBa, Generation R, and Generation Scotland) (Table 1). Within the group
between menarche to <40 years, mean ages ranged from 23.9 years in ALSPAC to
29.4 years in Generation R, while mean BMI values varied between 22.8 kg/m² in
ALSPAC and 24.5 kg/m² in Generation Scotland. Further information on the mean
and median ages and BMI measures are displayed in Table 1.

Table 1. Descriptive statistics for nulliparous women between menarche and <40
years, menarche and <20 years, 20 and <30 years and 30 and <40 years, across all
cohorts.
440

	Cohort	N	Age (years)		BMI (kg/m^2)	
			Mean (SD)	Median (Min-Max)	Mean (SD)	Median (Min-Max)
ALL (MENARCHE TO <40 YEARS)	ALSPAC	5047	23.92 (6.01)	24.00 (14.00-39.00)	22.79 (3.86)	21.98 (12.50-51.16)
	HUNT	7683	24.40 (5.04)	23.7 (12.80-39.90)	23.40 (3.99)	22.50 (15.34-52.20)
	MoBa	74906	28.51(6.19)	30.00 (14.00-39.00)	23.68 (4.19)	22.84 (8.11-50.21)
	Generation R	2479	29.44 (4.71)	30.13 (15.96-39.95)	23.07 (4.04)	22.09 (14.53 - 49.82)
	Generation Scotland	3059	26.29 (5.95)	26.00 (14.00-39.00)	24.52 (5.28)	23.24 (13.13-57.94)
MENARCHE TO <20 YEARS	ALSPAC	2047	17.78 (0.42)	17.75 (14.00-19.33)	22.79 (4.10)	21.92 (13.11-50.06)
	HUNT	1093	16.90 (2.01)	17.00 (12.80-19.90)	21.95 (3.07)	21.48 (15.34-46.87)
	MoBa	7826	14.75 (1.24)	14.00 (14.00-19.00)	20.92 (3.07)	20.45 (15.43-40.75)
	Generation R					
	Generation Scotland	430	18.15 (0.94)	18.00 (14.00-19.00)	22.88 (3.96)	22.05 (15.5-43.09)
20 TO <30 YEARS	ALSPAC	3520	24.91 (2.12)	24.00 (20.00-29.00)	23.61 (4.44)	22.52 (14.22-57.88)
	HUNT	5507	24.18 (2.69)	23.70 (20.00-29.90)	23.50 (3.99)	22.7 (15.60-52.20)
	MoBa	29375	26.22 (2.41)	27.00 (20.00-29.00)	23.90 (4.19)	20.97 (8.11-49.34)
	Generation R	1127	26.08 (2.86)	26.62 (20.01 - 29.99)	23.24 (4.47)	22.20 (14.53 - 49.82)
	Generation Scotland	1745	24.41 (2.81)	24.00 (20.00-29.00)	24.31 (5.03)	23.12 (13.13-54.95)
30 TO <40YEARS	ALSPAC	1054	32.65 (2.45)	32.00 (30.00-39.00)	22.72 (3.65)	21.97 (12.50-47.30)
	HUNT	1083	33.09 (2.60)	32.30 (30.00-39.90)	24.32 (4.45)	23.30 (17.00-48.50)
	MoBa	37669	33.16 (2.48)	33.00 (30.00-39.00)	24.09 (4.06)	21.26 (8.50-50.21)
	Generation R	1269	33.12 (2.25)	32.76 (30.00 - 39.95)	22.98 (3.67)	22.06 (16.90 - 43.34)
	Generation Scotland	884	33.98 (2.85)	34.00 (30.00-39.00)	25.72 (6.00)	24.05 (13.7-57.94)

441
442
443 *Lifestage-stratified genome-wide association studies (GWAS) and meta-analysis*
444

The primary meta-analysed GWAS for BMI in nulliparous women between menarche
and <40 years comprised a total of 90,115 individuals. The secondary meta-
analysed GWAS for BMI in nulliparous women between menarche to <20 years, 20
to <30 years and 30 to <40 years comprised a total of 10,966, 34,022 and 39,992,
respectively (Figure 1). For cohorts with repeat measures within one age band (e.g.,
menarche to <40 years), we took one measure with the largest sample size (e.g., it
only includes ALSPAC offspring BMI data from menarche to <20-year-olds). This
gave a total of 45 independent variants discovered across all time points.

Overall, 31, 3, 12 and 5 independent genetic variants were associated with BMI in
women between menarche to <40 years, menarche to <20 years, 20 to <30 years
and 30 to <40 years prior to giving birth, respectively, based on conventional
genome-wide corrections (i.e., $P<5\times10^{-08}$; Table S3).

Cochran's Q statistic was used to evaluate heterogeneity among the 31 instrumental
variables across the five cohort studies included in the primary analysis. To account
for   multiple   comparisons,   a Bonferroni   correction was   applied.   After
adjustment, none of the SNPs exhibited evidence of heterogeneity ($Q_{bonf}<0.05$),
suggesting consistent effect estimates across studies. This reinforces their validity in
downstream MR analyses, reducing concerns that study-level differences may
confound associations with the outcome.

We visualised the age-specific effect trajectories of these SNPs at each age group
(menarche to <20 years, 20 to <30 years and 30 to <40 years), with point size
inversely proportional to the standard error of the effect estimate (Figure S5). This
revealed two notable patterns of heterogeneity: (i) SNP effects in the 20 to <30-year
age group differ markedly from those in the menarche to <20-year and 30 to <40-
year age groups, and (ii) some SNPs show a reversal in effect after age 30. Among
45 independent variants, nine showed substantial heterogeneity across the three
age groups ($Q_{het}<0.05$) (Figure 3). Given that the proportion of individuals from each
cohort is comparable between the 20 to <30-year and 30 to <40-year age groups,
the swing in effect estimates observed in the 20 to <30-year group is unlikely to be
driven by a single cohort. These distinct patterns underscore age-specific
heterogeneity that would likely be overlooked by linear meta-regression, highlighting
the complexity of SNP effects on BMI over time.

 Figure 3. Plot illustrating the age-specific effect trajectories of individual SNPs with
 significant heterogeneity (QFDR < 0.05) on BMI across three defined age groups:
 menarche to <20 years, 20 to <30 years, and 30 to <40 years, in nulliparous women.

Each plot represents a SNP exhibiting significant heterogeneity (QFDR < 0.05),
illustrating its effect size (beta) across age intervals. Error bars denote 95%
confidence intervals.

Heritability, LD score regression and genetic correlation analysis

We quantified the proportion of variance of the four meta-analyses undertaken on BMI in nulliparous women at different ages of European ancestry that can be explained by our SNP sets using Linkage Disequilibrium (LD) Score regression (57). The GWAS summary statistic SNP-based heritability ranged from 0.11 (SE = 0.01) for BMI in nulliparous women between 30 and <40 year olds, to 0.23 (SE = 0.02) for BMI in nulliparous women between 20 to <30 year olds (Table 2). These results indicate that genetic factors play an important role in BMI, particularly in the younger age groups. The number of GWAS hits aligns with expectations, closely tracking with heritability ( ) and sample size, suggesting consistent polygenicity across age groups.

499 Table 2. Summary of meta-analysed genome-wide association results by age group
500 categories.
501

Metric	Age group category			
	BMI in nulliparous women between menarche and <40 years	BMI in nulliparous women between menarche and <20 years	BMI in nulliparous women between 20 and <30 years	BMI in nulliparous women between 30 and <40 years
	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)
Heritability (Observed Scale h^2)	0.19 (0.01)	0.21 (0.03)	0.23 (0.02)	0.11 (0.01)
Genomic Inflation Factor (Lambda GC)	1.27	1.07	1.17	1.09
LD Score Regression Intercept	1.01 (0.02)	1.01 (0.01)	1.00 (0.04)	1.01 (0.01)
Proportion of Inflation (Ratio)	0.03 (0.02)	0.13 (0.08)	0.01 (0.04)	0.07 (0.06)

502
The genetic correlations (r_G) observed between prepubertal body size (used as a
proxy for BMI) in females and BMI at different stages in nulliparous women from
menarche to <40 years reveal consistently strong associations, as expected when
investigating a similar phenotype (BMI and body size) across different life stages.
The r_G of 0.76 (SE = 0.02, P = 2.13×10^{-223}) between prepubertal body size in females
and BMI in nulliparous women <40 years indicates a high degree of shared genetic
influence. This trend was mirrored at more granular age intervals, with r_G values of
0.88, 0.74, and 0.71 for BMI in nulliparous women from menarche to <20, 20 to <30,
and 30 to <40 years, respectively (Figure 4). These results suggest prepubertal body
size has a slightly stronger genetic correlation in younger age groups, particularly for
BMI measured before age 20. Similarly, body size (used as a proxy for BMI) in later
life adult women shows strong genetic overlap with BMI measured in nulliparous
women at various age periods, with r_G values ranging from 0.68 (for BMI in
nulliparous women from menarche to <20 years) to 0.95 (for BMI in nulliparous
women aged 30 to <40 years). The consistently high r_G values across all
comparisons, particularly the near-perfect correlation between body size measured
in later life adult women and BMI in nulliparous women aged 30 to <40 (r_G = 0.95, SE
= 0.05), may reflect an enduring genetic influence of BMI from adolescence into later
reproductive years (Figure 4; Table S4). To generate the genetic correlation
heatmap, we calculated the r_G for measures with fully overlapping sample sizes. This

overlap led to inflation of the r_G estimate to be slightly greater than 1, and we capped
the r_G at a maximum value of 1.
525

526
527   *Figure 4. Genetic correlation heatmap for body mass index (BMI) and body size*
528   *(used as a proxy for BMI) across various age groups in females, spanning from*
529   *prepuberty through menarche and first birth to later adulthood.*
530
531   *Lifecourse Mendelian randomization (MR) analysis*
532
Univariable MR analyses using the 31 identified SNPs indicated strong evidence that
higher genetically predicted BMI in nulliparous women between menarche and <40
years reduced the risk of overall breast cancer (IVW odds ratio (OR), 95% CI: 0.24,
0.12 to 0.45, P□=□9.60×10^{-6}) (Figure 5; Table S5). Higher genetically predicted BMI
in nulliparous women between menarche and <40 years additionally reduced the risk
of most breast cancer subtypes, with the exception of the HER-2 enriched subtype.

In multivariable MR accounting for adult body size, there remained evidence that
higher genetically predicted BMI in nulliparous women between menarche and <40
years reduced the risk of overall breast cancer and most breast cancer subtypes,
with the exception of the HER-2 enriched subtype. There was very little evidence,
however, that higher genetically predicted BMI in nulliparous women between
menarche and <40 years remained protective of overall breast cancer or breast
cancer subtypes, after accounting for prepubertal body size.
546
In addition, univariable MR analyses using the 3 identified SNPs indicated strong
evidence that higher genetically predicted BMI in nulliparous women between
menarche and <20 years reduced the risk of overall breast cancer (IVW OR, 95% CI:
0.06, 0.03 to 0.12, $P = 7.40 \times 10^{-13}$). Higher genetically predicted BMI in this age
group was additionally associated with a reduced risk of all breast cancer subtypes.
After adjusting for adult body size in multivariable MR, there remained evidence that
higher genetically predicted BMI in nulliparous women under 20 years reduced the
risk of overall breast cancer and most subtypes, except for the HER-2 enriched
subtype. However, after accounting for prepubertal body size, there was very little
evidence that higher genetically predicted BMI in this age group decreased the risk
of overall breast cancer and its subtypes (Figure 5; Table S5).
558
There was some evidence that higher genetically predicted BMI in nulliparous
women between ages 20 and <30 using the 12 identified SNPs, as well as between
30 and <40 using the 5 identified SNPs, reduced the risk of overall breast cancer.
The HER-2 enriched subtype was an exception in the 30 to <40 age group, where
there was little evidence of an effect. There remained evidence in multivariable MR
that higher genetically predicted BMI in nulliparous women in these age groups
reduced breast cancer risk after accounting for adult body size, however, there
appeared to be an increased risk of the HER-2 enriched subtype in the 20 to <30-
year age group. Multivariable MR analyses, accounting for prepubertal body size,
again showed reduced evidence of a protective effect of genetically predicted BMI in
these age groups on overall breast cancer and its subtypes (Figure 5; Table S5).
Consistent patterns of associations were observed using the weighted median
method employed for robustness. In addition, results using the MR-Egger method
did not provide evidence that horizontal pleiotropy was responsible for the estimates
derived (Table S5).
574
575 Multivariable MR results should be interpreted with caution, however, since
576 conditional F-statistic was <10 for each of the BMI exposures included in these
577 models, indicating potential for weak instrument bias (Table S5).
578

579
Figure 5. Univariable and multivariable Mendelian randomization (MR) for BMI
between menarche and first birth on breast cancer (overall and subtype samples). A.
The total effects (univariable MR). B. The direct effect accounting for childhood body
size, and C. The direct effect accounting for adulthood body size (multivariable MR
(MVMR)). The plots present the odds ratio of breast cancer per standard deviation
(SD) increase in natural log-transformed BMI. Error bars indicate 95% confidence
intervals around the point estimate from inverse-variance weighted (IVW) MR and
IVW-MVMR analyses.
588
589 *Sensitivity analyses*
590
Our analyses to investigate potential collider bias indicated very little evidence that
genetically proxied parity associated with BMI in nulliparous women between
menarche and <40 years, menarche and <20 years, and 20 and <30 years. There
was some evidence that genetically proxied parity associated with lower BMI in
nulliparous women between 30 and <40 years (Table S6). These results suggest
collider bias due to selecting nulliparous women is likely to be of little concern within
this study.
598
599 After adjusting for age at menarche, the estimated effect of BMI in nulliparous
600 women between menarche and <40 years on overall breast cancer remains largely
601 consistent with the UVMR analyses (Table S7).
602

Discussion

In this study, we undertook GWAS and MR analyses within a lifecourse framework to (i) assess the consistency of the genetic effects of BMI across different life stages, and (ii) investigate the effects of genetically proxied BMI in nulliparous women between menarche and <40 years on the risk of overall breast cancer and seven subtypes. This work builds on previous research to further the investigation into the influence of BMI during critical periods on breast cancer risk (13, 14, 58). Motivated by recent findings suggesting that a larger prepubertal body size, used as a proxy for BMI, may offer protection against breast cancer risk, while later life body size shows very little effect, we aimed to better understand the interval between puberty and later life. Specifically, we focused on the period between menarche and first full-term pregnancy, a crucial window of vulnerability for later life breast cancer development.

We observed considerable variation in genetic effects on BMI across different life stages for nine of the 45 discovery variants identified in this study. In addition, genome-wide cross-lifestage genetic correlations demonstrated variation, e.g., when comparing prepubertal body size and later-life body size with BMI from menarche to 40 years. In the univariable MR analyses, higher BMI in nulliparous women from menarche to <40 years was found to consistently reduce risk of breast cancer, including BMI measured in the separate age periods within this life stage (menarche to <20 years, 20 to <30, and 30 to <40 years), and risk of overall breast cancer and its subtypes. These protective effects largely remained upon accounting for later life adult body size. However, when prepubertal body size was accounted for in a multivariable MR setting, the estimates attenuated toward the null, indicating weak evidence of a direct effect of BMI in nulliparous women on overall breast cancer and its subtypes. This suggests the protective effects observed in a univariable setting are largely driven by the influence that increased prepubertal body size has on breast cancer risk.

The findings of this study suggest that, following puberty, a higher BMI in nulliparous women no longer appears to provide substantial protection against breast cancer risk. Beyond the well-established link between the interval length from menarche to first birth and breast cancer risk, the pubertal period has been identified as a critical window for potential risk-reducing interventions (59). Like other windows of susceptibility, puberty is marked by cellular proliferation and tightly regulated tissue remodelling, driven by hormonal signalling and crosstalk between the mammary epithelium and stroma (60, 61).

There is evidence suggesting two distinct pathways contributing to altered breast cancer risk during the prepubertal and pubertal periods: one associated with greater body size in pre-pubertal years and the other with earlier age at menarche (13). While a larger body size in childhood is protective, it may also accelerate age at

menarche, which is itself a risk factor for breast cancer, suggesting that these
pathways are not only independent but may also interact in complex ways.
Furthermore, increased prepubertal body size has a decreasing effect on breast
density, while age at menarche has been linked to higher breast density, which is
another important risk factor for breast cancer (58, 62). This distinction between
pathways highlights the need to examine potential mediating factors, which may help
clarify the mechanisms at play. A deeper investigation into these separate but
intersecting pathways could reveal novel insights into breast cancer risk.
654
The relationship between body size and breast cancer risk is complex. In
conventional epidemiological settings, higher BMI has been linked to an increased
risk of breast cancer in postmenopausal women and a decreased risk of breast
cancer in premenopausal women (63-66). A plausible explanation includes the
differing levels of oestrogen exposure between women experiencing overweight and
normal-weight (67). Premenopausal women experiencing overweight tend to have
longer anovulatory cycles, which reduces their exposure to ovarian hormones,
potentially lowering their breast cancer risk. After menopause, fat tissue serves as
another source of oestrogen production, which increases breast cancer risk among
overweight women (68-71). Whilst our study did not specifically examine the
relationship between overweight status and breast cancer pre and post menopause,
effect estimates showed minimal variation between increased BMI and any of the
breast cancer subtypes investigated in our study, with the exception of HER-2
enriched. Specifically, increased BMI in the 20 to <30-year category shifted from
having a protective effect in univariable MR analyses to an increased risk of the
HER-2 enriched subtype after accounting for body size later in life, though evidence
supporting this effect is limited. There are likely complex interactions between body
fat distribution, metabolic health, and HER-2 driven cell growth, potentially explaining
why the HER-2 enriched subtype exhibited distinct patterns in response to higher
BMI at different ages. This pattern is not observed in Luminal B1 (HER2+/ER+)
tumours, suggesting that there may be a unique effect of HER-2 expression
specifically in non-hormonally regulated tumours.
677
This study is an important and novel analysis with multiple strengths. It focuses on a
specific age range where the protective effect of BMI on breast cancer risk begins to
wane —an insight not previously achieved using causal inference methods. By
examining this critical period between menarche and first birth, we enhance
understanding on the potential interaction of nulliparity and BMI on breast cancer
development. Focusing on this timeframe also allowed us to obtain an estimate that
minimised the confounding effects introduced by the physiological changes
associated with a first pregnancy. To strengthen the analysis, we integrated data
from five large European longitudinal cohort studies, generating robust GWAS
results on BMI. This approach allowed us to gain key insights into the consistency of
BMI-related genetic effects across different stages of life. In addition, these data are
not only useful for this particular study but also offer a valuable resource for future

research into the effects of BMI in women at these life stages on other health
outcomes.

This study has several limitations that should be considered when interpreting the
findings. First, low conditional F-statistics were observed in the MVMR analysis,
indicating potential for weak instrument bias. As a result, our MVMR findings should
be interpreted with some caution. Second, while we combined data from five large
European longitudinal cohorts, the sample size remains smaller (N=90,115) than that
available for comparable measures of prepubertal and later-life body size derived
using in UK Biobank data (N=246,511). This reduced sample size may limit statistical
power for detecting smaller effect sizes. Third, used a prepubertal GWAS based on
reported body size rather than measured BMI, as it offered a much larger sample
size than any other GWAS of BMI at this life stage. However, this choice may distort
MVMR analysis due to measurement error or differences in variance of effect sizes,
and future work to precisely estimate childhood body size genetic effects are
warranted. Fourth, there is the possibility of participant overlap between the HUNT
and MoBa cohorts. While HUNT recruited individuals from Trøndelag County,
Norway, MoBa had a national recruitment strategy. Some participants in HUNT may
have also participated in MoBa, which could introduce a degree of sample
duplication. Lastly, as our analysis was restricted to individuals of European
ancestry, the generalisability of our findings to other populations is limited. Further
research is needed to confirm these findings in more diverse populations.

Conclusion

This study offers novel insights into the genetic influences on BMI across different
life stages and its causal relationship with breast cancer risk, focusing on the period
between menarche and under 40 years in nulliparous women as a key window of
susceptibility. Findings suggest that while a higher BMI during this interval may
initially appear protective against breast cancer, this effect diminishes after
accounting for prepubertal body size, used as a proxy for BMI, indicating that the
observed protective effects are largely driven by the influence of increased
prepubertal body size on breast cancer risk. These results have important
implications for breast cancer prevention, highlighting the prepubertal and pubertal
period as a critical life stages for potential interventions.

References.

725   **References.**
726
1.   Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al.
Current and future burden of breast cancer: Global statistics for 2020 and 2040. The
Breast. 2022;66:15-23.
2.   Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations
Tool, based on 2021 submission data (1999–2020): U.S. Department of Health and
Human Services, Centers for Disease Control and Prevention and National Cancer
Institute. Updated June 2024. [Available from: www.cdc.gov/cancer/dataviz.
3.   Liu Y, Tobias DK, Sturgeon KM, Rosner B, Malik V, Cespedes E, et al.
Physical activity from menarche to first pregnancy and risk of breast cancer.
International Journal of Cancer. 2016;139(6):1223-30.
4.   Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts
early: prevention must also. Breast Cancer Res Treat. 2014;145(3):567-79.
5.   Ciwinska M, Messal HA, Hristova HR, Lutz C, Bornes L, Chalkiadakis T, et al.
Mechanisms that clear mutations drive field cancerization in mammary tissue.
Nature. 2024;633(8028):198-206.
6.   Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol
intake between menarche and first pregnancy: a prospective study of breast cancer
risk. J Natl Cancer Inst. 2013;105(20):1571-8.
7.   Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks
Hum. 2010;96:3-1383.
8.   Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic
epidemiology contribute to understanding environmental determinants of disease?
Int J Epidemiol. 2003;32(1):1-22.
9.   Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et
al. Mendelian randomization. Nat Rev Methods Primers. 2022;2.
10.   Power GM, Sanderson E, Pagoni P, Fraser A, Morris T, Prince C, et al.
Methodological approaches, challenges, and opportunities in the application of
Mendelian randomisation to lifecourse epidemiology: A systematic literature review.
Eur J Epidemiol. 2024;39(5):501-20.
11.   Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
multivariable Mendelian randomization in the single-sample and two-sample
summary data settings. Int J Epidemiol. 2019;48(3):713-27.
12.   Sanderson E, Richardson TG, Morris TT, Tilling K, Davey Smith G. Estimation
of causal effects of a time-varying exposure at multiple time points through
multivariable mendelian randomization. PLoS Genet. 2022;18(7):e1010290.
13.   Vabistsevits M, Davey Smith G, Sanderson E, Richardson TG, Lloyd-Lewis B,
Richmond RC. Deciphering how early life adiposity influences breast cancer risk
using Mendelian randomization. Commun Biol. 2022;5(1):337.
14.   Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G. Use of
genetic variation to separate the effects of early and later life adiposity on disease
risk: mendelian randomisation study. BMJ. 2020;369:m1203.
15.   Hao Y, Xiao J, Liang Y, Wu X, Zhang H, Xiao C, et al. Reassessing the causal
role of obesity in breast cancer susceptibility: a comprehensive multivariable
Mendelian randomization investigating the distribution and timing of exposure. Int J
Epidemiol. 2023;52(1):58-70.
16.   Jensen BW, Aarestrup J, Blond K, Jørgensen ME, Renehan AG, Vistisen D,
et al. Childhood body mass index trajectories, adult-onset type 2 diabetes, and
obesity-related cancers. J Natl Cancer Inst. 2023;115(1):43-51.

17.   Fagherazzi G, Guillas G, Boutron-Ruault M-C, Clavel-Chapelon F, Mesrine S.
Body shape throughout life and the risk for breast cancer at adulthood in the French
E3N cohort. European Journal of Cancer Prevention. 2013;22(1):29-37.
18.   Song M, Willett WC, Hu FB, Spiegelman D, Must A, Wu K, et al. Trajectory of
body shape across the lifespan and cancer risk. Int J Cancer. 2016;138(10):2383-95.
19.   Richardson TG, Urquijo H, Holmes MV, Davey Smith G. Leveraging family
history data to disentangle time-varying effects on disease risk using lifecourse
mendelian randomization. European Journal of Epidemiology. 2023;38(7):765-9.
20.   Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al.
Association analysis identifies 65 new breast cancer risk loci. Nature.
2017;551(7678):92-4.
21.   Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al.
Genome-wide association study identifies 32 novel breast cancer susceptibility loci
from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572-81.
22.   Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G,
et al. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC
mothers cohort. Int J Epidemiol. 2013;42(1):97-110.
23.   Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al.
Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal
Study of Parents and Children. Int J Epidemiol. 2013;42(1):111-27.
24.   Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al.
The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the
enrolled sample of index children in 2019. Wellcome Open Res. 2019;4:51.
25.   Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)--a metadata-driven methodology and workflow
process for providing translational research informatics support. J Biomed Inform.
2009;42(2):377-81.
26.   Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP,
et al. Cohort Profile Update: The HUNT Study, Norway. International Journal of
Epidemiology. 2022;52(1):e80-e91.
27.   Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et
al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42(4):968-77.
28.   Irgens LM. The Medical Birth Registry of Norway. Epidemiological research
and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-
9.
29.   Moen G-H, Brumpton B, Willer C, Åsvold BO, Birkeland KI, Wang G, et al.
Mendelian randomization study of maternal influences on birthweight and future
cardiometabolic risk in the HUNT cohort. Nature Communications. 2020;11(1):5404.
30.   Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, et
al. The HUNT study: A population-based cohort for genetic research. Cell Genom.
2022;2(10):100193.
31.   Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort
Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). International
Journal of Epidemiology. 2016;45(2):382-8.
32.   Paltiel L, Anita H, Skjerden T, Harbak K, Bækken S, Nina Kristin S, et al. The
biobank of the Norwegian Mother and Child Cohort Study – present status. Norsk
Epidemiologi. 2014;24(1-2).
33.   Kooijman MN, Kruithof CJ, van Duijn CM, Duijts L, Franco OH, van IMH, et al.
The Generation R Study: design and cohort update 2017. Eur J Epidemiol.
2016;31(12):1243-64.

34. Ghatan S, de Vries J, Pingault J-B, Jaddoe VW, Cecil C, Felix JF, et al.
Genetic Nurture: Estimating the direct genetic effects of pediatric anthropometric
traits. medRxiv. 2024:2024.12.10.24318796.
35. Næss M, Kvaløy K, Sørgjerd EP, Sætermo KS, Norøy L, Røstad AH, et al.
Data Resource Profile: The HUNT Biobank. Int J Epidemiol. 2024;53(3).
36. Corfield EC, Shadrin AA, Frei O, Rahman Z, Lin A, Athanasiu L, et al. The
Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource:
MoBaPsychGen pipeline v.1. bioRxiv. 2024:2022.06.23.496289.
37. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics. 2010;26(17):2190-1.
38. Ani A, van der Most PJ, Snieder H, Vaez A, Nolte IM. GWASinspector:
comprehensive quality control of genome-wide association study results.
Bioinformatics. 2021;37(1):129-30.
39. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al.
LD Score regression distinguishes confounding from polygenicity in genome-wide
association studies. Nature genetics. 2015;47(3):291.
40. Paria SS, Rahman SR, Adhikari K. fastman: A fast algorithm for visualizing
GWAS results using Manhattan and Q-Q plots. bioRxiv. 2022:2022.04.19.488738.
41. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
generation PLINK: rising to the challenge of larger and richer datasets. Gigascience.
2015;4:7.
42. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE,
et al. An integrated map of genetic variation from 1,092 human genomes. Nature.
2012;491(7422):56-65.
43. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK
biobank: an open access resource for identifying the causes of a wide range of
complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
44. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK
Biobank resource with deep phenotyping and genomic data. Nature.
2018;562(7726):203-9.
45. Brandkvist M, Bjørngaard JH, Ødegård RA, Åsvold BO, Smith GD, Brumpton
B, et al. Separating the genetics of childhood and adult obesity: a validation study of
genetic scores for body mass index in adolescence and adulthood in the HUNT
Study. Hum Mol Genet. 2021;29(24):3966-73.
46. Richardson TG, Mykkänen J, Pahkala K, Ala-Korpela M, Bell JA, Taylor K, et
al. Evaluating the direct effects of childhood adiposity on adult systemic metabolism:
a multivariable Mendelian randomization analysis. Int J Epidemiol. 2021.
47. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The
MR-Base platform supports systematic causal inference across the human
phenome. Elife. 2018;7:e34408.
48. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and
Scope. Cold Spring Harb Perspect Med. 2022;12(1).
49. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression.
International journal of epidemiology. 2015;44(2):512-25.
50. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in
Mendelian randomization with some invalid instruments using a weighted median
estimator. Genetic epidemiology. 2016;40(4):304-14.

51.   Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and
pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat
Med. 2021;40(25):5434-52.
52.   Menarche, menopause, and breast cancer risk: individual participant meta-
analysis, including 118 964 women with breast cancer from 117
epidemiological studies. The Lancet Oncology. 2012;13(11):1141-51.
53.   Dall GV, Britt KL. Estrogen Effects on the Mammary Gland in Early and Late
Life and Breast Cancer Risk. Front Oncol. 2017;7:110.
54.   Juul F, Chang VW, Brar P, Parekh N. Birth weight, early life weight gain and
age at menarche: a systematic review of longitudinal studies. Obes Rev.
2017;18(11):1272-88.
55.   Prince C, Howe LD, Sharp GC, Fraser A, Richmond RC. Establishing the
relationships between adiposity and reproductive factors: a multivariable Mendelian
randomization analysis. BMC Med. 2023;21(1):350.
56.   R Core Team. R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2020.
57.   Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et
al. LD Hub: a centralized database and web interface to perform LD score regression
that maximizes the potential of summary level GWAS data for SNP heritability and
genetic correlation analysis. Bioinformatics. 2017;33(2):272-9.
58.   Vabistsevits M, Davey Smith G, Richardson TG, Richmond RC, Sieh W,
Rothstein JH, et al. Mammographic density mediates the protective effect of early-life
body size on breast cancer risk. Nat Commun. 2024;15(1):4021.
59.   Krisanits B, Randise JF, Burton CE, Findlay VJ, Turner DP. Pubertal
mammary development as a "susceptibility window" for breast cancer disparity. Adv
Cancer Res. 2020;146:57-82.
60.   Martinson HA, Lyons TR, Giles ED, Borges VF, Schedin P. Developmental
windows of breast cancer risk provide opportunities for targeted chemoprevention.
Exp Cell Res. 2013;319(11):1671-8.
61.   Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the
microenvironment: Links to cancer. J Carcinog. 2013;12:19.
62.   Lloyd R, Pirikahu S, Walter J, Cadby G, Warrington N, Perera D, et al. The
Prospective Association between Early Life Growth and Breast Density in Young
Adult Women. Cancers [Internet]. 2024; 16(13).
63.   Tran TXM, Chang Y, Choi HR, Kwon R, Lim G-Y, Kim EY, et al. Adiposity,
Body Composition Measures, and Breast Cancer Risk in Korean Premenopausal
Women. JAMA Network Open. 2024;7(4):e245423-e.
64.   van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom
AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast
cancer risk. Am J Epidemiol. 2000;152(6):514-27.
65.   van den Brandt PA, Ziegler RG, Wang M, Hou T, Li R, Adami HO, et al. Body
size and weight change over adulthood and risk of breast cancer by menopausal and
hormone receptor status: a pooled analysis of 20 prospective cohort studies. Eur J
Epidemiol. 2021;36(1):37-55.
66.   Dehesh T, Fadaghi S, Seyedi M, Abolhadi E, Ilaghi M, Shams P, et al. The
relation between obesity and breast cancer risk in women by considering
menstruation status and geographical variations: a systematic review and meta-
analysis. BMC Women's Health. 2023;23(1):392.
67.   Friedenreich CM. Review of anthropometric factors and breast cancer risk.
Eur J Cancer Prev. 2001;10(1):15-32.

68. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty
CL, et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A
Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
JAMA Oncol. 2015;1(5):611-21.
69. Glassman I, Le N, Asif A, Goulding A, Alcantara CA, Vu A, et al. The Role of
Obesity in Breast Cancer Pathogenesis. Cells. 2023;12(16).
70. Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land
SR, et al. Body mass index and the risk for developing invasive breast cancer among
high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer
Prev Res (Phila). 2012;5(4):583-92.
71. Zhao P, Xia N, Zhang H, Deng T. The Metabolic Syndrome Is a Risk Factor
for Breast Cancer: A Systematic Review and Meta-Analysis. Obes Facts.
2020;13(4):384-96.

Acknowledgements.

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The authors would like to thank the research participants of the HUNT study which is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The HUNT genotype quality control and imputation has been conducted by the K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU. We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this on-going cohort study. We thank the Norwegian Institute of Public Health (NIPH) for generating genomic data as part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (#223273), South East Norway Health Authorities and Stiftelsen Kristian Gerhard Jebsen, and conducted by deCODE Genetics. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing quality control and imputation of the data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. The MoBa analyses were performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT Department (USIT) (tsd-drift@usit.uio.no). The analyses were performed using resources provided by Sigma2 - the National Infrastructure for High-Performance Computing and Data Storage in Norway. The Generation R Study is conducted by Erasmus MC in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam, and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We gratefully acknowledge the contribution of children and parents, general practitioners, hospitals, midwives, and pharmacies in Rotterdam. The generation and management of GWAS genotype data for the Generation R Study was done at the Human Genomics Facility, HuGe-F, housed

within the Laboratory for Population Genomics of the Department of Internal Medicine at Erasmus MC. Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, The Netherlands. We thank Pascal Arp, Gaby van Dijk, Marijn Verkerk, Samuel Gathan, Dr. Linda Broer and Jard de Vries for their help in creating, managing and QCing the GWAS database.

Sources of funding.

The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. GMP, AH, GL, ES, RR, GH, and GDS were supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00032/1). GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The genotyping in HUNT was supported by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway (RCN); The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. LB, BOA, and BMB work in a research unit financially supported by the Liaison Committee for education, research and innovation in Central Norway and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU. This study used data from Medical Birth Registry of Norway (MBRN). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z. CH was supported by an MRC University Unit core grant MC_UU_00007/10 (QTL in Health and Disease program). BLL acknowledges support from the University of Bristol (Vice-Chancellor's Research Fellowship), Academy of Medical Sciences/Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/British Heart Foundation/Diabetes UK Springboard Award (SBF003/1170), Elizabeth Blackwell Institute for Health Research (University of Bristol), and Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z) and Wellcome Trust Career Development Award (227849/Z/23/Z). AH was supported by the Research Council of Norway (#336085) and the South-Eastern Norway Regional Health Authority (#2020022; #2922083; #2019097; #2018059; #2021045). The general design of the Generation R Study is made possible by financial support from Erasmus MC, University Medical

Center Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organization for Scientific Research (NWO), the Ministry of Health, Welfare and Sport, and the Ministry of Youth and Families. The parental genotyping in Generation R was supported by the ERC under the European Union's Horizon 2020 research and innovation programme (iRISK; grant agreement No 863981). This project received funding from the European Union's Horizon Europe Research and Innovation Programme under grant agreement nº 101137146 (STAGE project). UK participants in Horizon Europe Project STAGE are supported by UKRI grant numbers 10112787 (Beta Technology), 10099041 (University of Bristol) and 10109957 (Imperial College London).

Research Ethics and Informed Consent.

Informed consent was obtained from all participants and ethical approval was obtained from the Regional Committee for Medical and Health Research Ethics, Central Norway (REK Central application number 2018/2488) (HUNT), the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (ALSPAC), the Medical Ethical Committee of Erasmus MC, University Medical Center Rotterdam, approved the study (MEC 198.782/2001/31) (Generation R), and The Regional Committees for Medical and Health Research Ethics (REK application number 2016/1702) (MoBa). Written consent was obtained from all participants in Generation Scotland. All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021).

Conflicts of interest.

Authors declare no conflict of interest.

Data and computing code availability.

All genetic instruments derived in this study are in the supplementary tables. Genome-wide association study summary statistics will be made available on a public repository upon publication.

None of the material has been published or is under consideration for publication elsewhere.